The MHRA has clarified the regulatory status of Ambient Voice Technologies (AVTs) used across the NHS. Discover what this means for AI developers, healthcare providers, and digital health innovators, and why regulatory clarity is accelerating the safe adoption of AI-enabled clinical documentation.
Artificial Intelligence is rapidly transforming clinical practice, with one of the fastest-growing applications being Ambient Voice Technologies (AVTs). These AI-enabled systems can automatically capture conversations between clinicians and patients, generate structured clinical notes, draft referral letters, and reduce administrative burden—allowing healthcare professionals to spend more time focusing on patient care rather than documentation.
As adoption accelerates across the NHS, one question has become increasingly important:
When does an AI-powered ambient voice product become a regulated medical device?
The Medicines and Healthcare products Regulatory Agency (MHRA) has now provided much-needed regulatory clarity, helping developers, NHS organisations, and healthcare professionals understand how these innovative technologies fit within the UK medical device framework. Together with NHS England's implementation guidance, this marks another important milestone in the UK's ambition to become a global leader in safe, responsible AI adoption in healthcare.
Ambient voice technologies have evolved rapidly over the last few years.
Earlier generations primarily converted speech into text through traditional speech recognition and digital dictation. Today's AI-enabled systems combine automatic speech recognition with Generative AI and Large Language Models (LLMs) to produce structured consultation summaries, clinic letters, coding suggestions and workflow support.
While these capabilities offer significant productivity gains, they also raise important regulatory questions:
The MHRA's clarification helps answer these questions by focusing on a fundamental principle of medical device regulation: intended purpose.
The MHRA makes clear that not every ambient voice technology is automatically a medical device.
Whether regulation applies depends on what the software is intended to do rather than the technology itself.
For example, products that simply:
may not fall within the scope of UK medical device regulations, provided they do not perform functions that influence clinical decisions.
However, the regulatory position changes where AI begins to perform functions such as:
In these situations, the software is likely to be considered Software as a Medical Device (SaMD) and must comply with the UK Medical Devices Regulations before deployment.
One of the most important aspects of the guidance is its recognition of the capabilities—and limitations—of Generative AI.
Large Language Models may unintentionally generate outputs that extend beyond their intended purpose, including suggesting diagnoses, identifying potential missed conditions or making treatment recommendations.
Even when these outputs are not deliberately designed, developers are expected to minimise their occurrence through:
This reflects an increasingly important regulatory principle for AI: human oversight remains essential.
Alongside the MHRA clarification, NHS England has published detailed implementation guidance to help healthcare organisations safely adopt AI-enabled ambient scribing products.
Rather than focusing solely on procurement, the guidance encourages organisations to consider the complete implementation lifecycle.
Key areas include:
Healthcare organisations should independently verify whether products have been correctly classified under UK medical device regulations and, where applicable, confirm that they are registered with the MHRA.
For regulated products, appropriate UKCA certification—or a valid CE mark during the transition period—must be in place before clinical deployment.
Ambient voice technologies process sensitive patient information.
Implementation therefore requires careful consideration of:
The guidance emphasises early engagement with Information Governance and cybersecurity teams during procurement and implementation.
Even where AI supports documentation, clinicians remain responsible for verifying outputs before they become part of the patient's medical record.
The guidance reinforces that AI-generated documentation should support—not replace—clinical judgement.
Transparency, accountability and traceability remain central principles throughout implementation.
To support consistent adoption across the NHS, NHS England has established the Ambient Voice Technology (AVT) Supplier Registry.
The registry provides NHS organisations with access to supplier evidence intended to support local procurement and assurance activities.
Among other expectations, suppliers are required to demonstrate:
The registry is not an approved purchasing framework, nor does it represent endorsement of individual suppliers, but it provides NHS organisations with a more structured starting point when evaluating available technologies.
For digital health companies developing AI-enabled clinical products, the guidance provides greater certainty around regulatory expectations.
Developers should now consider regulatory strategy much earlier in product development by:
Building regulatory considerations into product development early can significantly reduce delays later in the commercialisation process.
The publication of this guidance reflects a broader trend in UK healthcare regulation.
Rather than limiting innovation, regulators are seeking to provide clearer pathways that enable AI technologies to be introduced safely and responsibly.
Initiatives such as:
all point towards a more mature regulatory ecosystem where innovation and patient safety evolve together.
For AI developers, this creates greater predictability.
For healthcare providers, it offers greater confidence.
For patients, it supports the safe adoption of technologies that can improve both clinical efficiency and quality of care.
Ambient Voice Technologies have the potential to fundamentally reshape clinical documentation, reduce administrative burden, and improve clinician-patient interactions across the NHS.
The MHRA's clarification provides exactly what the sector has been seeking: a practical, risk-based interpretation of when these technologies fall within medical device regulation and what developers and healthcare organisations need to do to ensure safe implementation.
As AI capabilities continue to evolve, regulatory clarity will become just as important as technological innovation. Organisations that combine strong product development with robust regulatory strategy will be best positioned to deliver trusted AI solutions into routine clinical practice.
Whether you are developing an AI-enabled ambient voice solution, determining Software as a Medical Device (SaMD) status, preparing technical documentation, or planning your UK regulatory strategy, Regvista provides expert regulatory support to help innovators navigate the evolving UK AI regulatory landscape with confidence.
At Regvista, we remain committed to support biopharmaceutical leaders navigating their transformative journey—bringing cutting-edge therapies to market faster and safer. Please feel free to contact us by submitting your enquiry to deployment@regvista.co.uk
02-Aug-26